Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Update

Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 8,520,000 shares, a drop of 18.2% from the November 15th total of 10,410,000 shares. Approximately 11.9% of the company’s stock are short sold. Based on an average trading volume of 655,500 shares, the short-interest ratio is currently 13.0 days.

Insider Activity

In related news, CEO Gary S. Gillheeney sold 18,416 shares of Organogenesis stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $3.65, for a total value of $67,218.40. Following the completion of the transaction, the chief executive officer now directly owns 3,400,778 shares in the company, valued at approximately $12,412,839.70. This trade represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 216,916 shares of company stock worth $784,832 over the last ninety days. Corporate insiders own 36.90% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

Hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors bought a new stake in shares of Organogenesis during the third quarter valued at approximately $36,000. Pallas Capital Advisors LLC acquired a new stake in Organogenesis in the second quarter worth approximately $38,000. Delap Wealth Advisory LLC acquired a new stake in Organogenesis in the second quarter worth approximately $40,000. Intech Investment Management LLC acquired a new stake in Organogenesis in the third quarter worth approximately $43,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares during the period. Institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Down 3.7 %

NASDAQ:ORGO traded down $0.13 during mid-day trading on Friday, reaching $3.40. The stock had a trading volume of 533,181 shares, compared to its average volume of 843,073. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The stock’s 50 day simple moving average is $3.42 and its two-hundred day simple moving average is $2.98. Organogenesis has a 1-year low of $2.16 and a 1-year high of $4.70. The company has a market capitalization of $450.77 million, a price-to-earnings ratio of -56.67 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The firm had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same quarter last year, the company posted $0.02 earnings per share. Equities analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.